| 產(chǎn)品編號(hào) | bsm-51174M |
| 英文名稱(chēng) | Mouse Anti-EpCAM antibody |
| 中文名稱(chēng) | 上皮細(xì)胞粘附分子（CD326）單克隆抗體 |
| 別 名 | Adenocarcinoma associated antigen; CD326; CD326 antigen; Cell surface glycoprotein Trop 1; CO17 1A; EGP; EGP40; Ep CAM; Epithelial cell surface antigen; Epithelial cellular adhesion molecule; Epithelial glycoprotein; GA733 2; hEGP 2; KS 1/4 antigen; KSA; Lymphocyte antigen 74; M1S2; M4S1; Major gastrointestinal tumor associated protein GA733 2; MIC18; MK 1; TACD1; TACSTD1; TROP1; Tumor associated calcium signal transducer 1. |
 |
Specific References (1) | bsm-51174M has been referenced in 1 publications.
[IF=8.758] Zeyu Li. et al. Imaging-Guided Chemo–Photothermal Polydopamine Carbon Dots for EpCAM-Targeted Delivery toward Liver Tumor. Acs Appl Mater Inter. 2021;XXXX(XXX):XXX-XXX IF ; Human.
|
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 細(xì)胞粘附分子 細(xì)胞表面分子 |
| 抗體來(lái)源 | Mouse |
| 克隆類(lèi)型 | Monoclonal |
| 克 隆 號(hào) | 10A8 |
| 交叉反應(yīng) | (predicted: Human) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 35kDa |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human EpCAM: 50-100 <Extracellular> |
| 亞 型 | IgG1 |
| 純化方法 | affinity purified by Protein G |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy. [provided by RefSeq, Dec 2008] Function: May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E. Subunit: Monomer. Interacts with phosphorylated CLDN7. Subcellular Location: Lateral cell membrane; Single-pass type I membrane protein. Cell junction, tight junction. Note=Co-localizes with CLDN7 at the lateral cell membrane and tight junction. Tissue Specificity: Highly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma. Post-translational modifications: Hyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability. DISEASE: Defects in EPCAM are the cause of diarrhea type 5 (DIAR5) [MIM:613217]. It is an intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum. Defects in EPCAM are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM. Similarity: Belongs to the EPCAM family. Contains 1 thyroglobulin type-1 domain. SWISS: P16422 Gene ID: 4072 Database links: Entrez Gene: 4072 Human Entrez Gene: 17075 Mouse Omim: 185535 Human SwissProt: P16422 Human SwissProt: Q99JW5 Mouse Unigene: 542050 Human Unigene: 4259 Mouse Unigene: 106481 Rat |
